From Kirsten Pilatti CEO BCNA Dear members,
I am so thrilled to be able to let you know that all our
great lobbying has tonight taken a significant step forward to helping
women living with me...
Published 7 years ago
Version 1.0
Blog Post
This is not hard.
One of three things happened:
1. The Pfizer/Novartis submission was specific for women only.
2 PBAC recommended it for women only and was specific in that recommendation.
3. The health ministry stipulated PBS use in women only.
It would be nice to know where did that start. It is true that if we are following the States - Their FDA approval specifies women only.
The problem with BC in men is the numbers are not there for big studies/big Pharma - it being rarer means that men are diagnosed late, have fewer options and are more likely to die from BC.
One of three things happened:
1. The Pfizer/Novartis submission was specific for women only.
2 PBAC recommended it for women only and was specific in that recommendation.
3. The health ministry stipulated PBS use in women only.
It would be nice to know where did that start. It is true that if we are following the States - Their FDA approval specifies women only.
The problem with BC in men is the numbers are not there for big studies/big Pharma - it being rarer means that men are diagnosed late, have fewer options and are more likely to die from BC.